Renal Cell Carcinoma Treatment Study

Clinical Trial Title

Clinical trial with combination therapies in immuno-oncology in advanced renal cell carcinoma.

Clinical Trial Protocol Description:

To provide combination therapies in treatment for patients with advanced renal cell carcinoma and to collect additional data on treatment safety.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have advanced (not amenable to curative surgery or radiation treatment) or metastatic (American Joint Committee on Cancer Stage IV) renal cell carcinoma.
  • Have a histological confirmation of renal cell carcinoma with a clear-cell component.
  • Can be anti-PD-1, anti-PD-L1, or anti-CTLA-4 naïve or experienced.
  • Have at least 1 lesion with measurable disease.

You will be excluded from the study if any of the following criteria apply to you:

  • Have suspected, known, or progressive CNS metastases; have untreated CNS metastases; or have the CNS as the only site of disease.
  • Have received any anti-cancer treatment (eg, chemotherapy, radiotherapy [except for palliative radiotherapy, which can be received up to 2 weeks prior to study treatment]; biologics; or immunotherapies, including investigational treatments) within 4 weeks prior to the first dose of study treatment.
  • Have active, known, or suspected autoimmune disease.
  • Have uncontrolled or significant cardiovascular disease.

This is a partial list of inclusion and exclusion criteria.

Study Details

Clinical Trial Investigator

Timothy Kuzel, MD

Contact Information

Rush Cancer Center Clinical Trials Office